In several AD murine models, selective HDAC6 inhibitor tubastatin A and selective SIRT1 inhibitor sirtinol attenuated symptoms associated with AD, accompanied by reduced expression of PGE2 and COX2, and serum levels of TSLP and chemokine CXCL13 [251]. Here, TSLP is linked to Alzheimer disease.